, Tracking Stock Market Picks
Enter Symbol:
Oncogenex Technologies Inc. (OGXI) [hlAlert]

down 91.99 %

Oncogenex Technologies Inc. (OGXI) rated Overweight by Thomas Weisel

Posted on: Tuesday,  Aug 25, 2009  8:25 AM ET by Thomas Weisel

Thomas Weisel rated Overweight Oncogenex Technologies Inc. (NASDAQ: OGXI) on 08/25/2009, when the stock price was $32.60. Since
then, Oncogenex Technologies Inc. has lost 91.99% as of 01/22/2016's recent price of $2.61.
If you would have followed this Thomas Weisel's recommendation on OGXI, you would have lost 91.99% of your investment in 2341 days.

OncoGenex Pharmaceuticals Inc., formerly Sonus Pharmaceuticals, Inc., is a biopharmaceutical company engaged in the development and commercialization of cancer therapies that address treatment resistance in cancer patients. The Company has five product candidates in its pipeline, with each product candidate having a distinct mechanism of action and representing an opportunity for cancer drug development. OncoGenex? product candidates OGX-011, OGX-427 and OGX-225 focus on mechanisms of treatment resistance in cancer patients and are designed to address treatment resistance by blocking the production of specific proteins. Product candidate SN2310 is a camptothecin for the treatment of cancer. Camptothecins are potent anticancer agents that belong to the family of drugs called topoisomerase I inhibitors that bind reversibly to the TOPO-I-DNA complex causing breaks in the DNA strands during replication resulting in cell death.

At Thomas Weisel Partners, the role of Research is to contribute to our clients' decision process in ways that lead to better investment decisions. We cover the key growth sectors of the economy including Consumer, Energy, Financial Services, Healthcare, Internet, Media & Telecom, Metals & Mining and Technology.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/25/2009 8:25 AM Buy
as of 12/31/2009
1 Week down  -26.24 %
1 Month down  -47.68 %
3 Months down  -54.16 %
1 YTD down  -49.38 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy